Dr. Chen received his bachelor’s degree in Pharmacy from National Taiwan University. Following this, he earned his Ph.D. in 2012 from the Pharmacological Institute at National Taiwan University under the supervision of Prof. Che-Min Teng, and continued his postdoctoral research focusing on epigenetic regulation in cancer and the discovery of novel HDAC inhibitors. He then joined Dr. Yun Yen’s laboratory as a postdoctoral fellow to develop novel anticancer agents targeting FGFR signaling pathways. In 2016, Dr. Chen transitioned to an academic role as an Assistant Professor in the Department of Pharmacology, School of Medicine at Taipei Medical University (TMU). Dr. Chen is also the administrative teacher of International Ph.D. Program in Medicine, College of Medicine, TMU.

Professional experience

• Associate professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University (Aug 2020~present)
• Assistant professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University (Mar 2016~July 2020)
• Postdoctoral Research at Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University (Mar 2014-Mar 2016)
• Postdoctoral Research at Genomics Research Center, Academia Sinica (July 2013-Feb 2014)
• Postdoctoral Research at Pharmacology Institute, National Taiwan University (Feb 2012-June 2013) 

Professional membership

• Active Member of the American Association for Cancer Research (AACR)
• Permanent Member of the Pharmacological Society in Taiwan
• Permanent Member of the Natural Medicine Society of Taiwan

Training as a pharmacologist,  Dr. Chen is dedicated to the research of cancer biology and drug discovery. His work has focused on developing novel therapeutic targets and small molecule compounds for treating bladder cancer. Dr. Chen has identified two therapeutic targets in bladder cancer: PIK3C3 and CK1δ. He has successfully developed MPT0L145, a first-in-class PIK3C3/FGFR inhibitor, which displays promising potential for clinical applications. Dr. Chen has also contributed to the understanding of natural compounds with anticancer properties, such as Cucurbitacin E and Stellettin B, which induce apoptosis and autophagy in cancer cells. Currently, Dr. Chen’s research team also focus on identifying the therapeutic potential and molecular mechanisms of natural products in pediatric high-grade glioma. Dr. Chen's dedication to research and education continues to inspire students and colleagues alike. His ongoing efforts aim to translate these scientific discoveries into effective clinical treatments for cancer patients. Chen lab welcome potential young scientists to join the research team.

Training skills

Molecular and Cellular Biology

• Gene regulation and transcription factors
• Epigenetics/Transcriptomics/Proteomics
• Cell cycle analysis

Cancer Biology

• Autophagy/Necroptosis/Ferroptosis
• Cell culture and animal models of cancer research
• Extracellular vesicle analysis 

Experimental and Molecular Therapeutics

• Molecular pharmacology
• Drug discovery/combination
• Mode of drug action
• Drug resistance